Malaria has long been a global scourge, killing some 500,000 people a year, more than half of them children under 5. But that may be about to change, thanks to the introduction of a malaria vaccine—the first vaccine ever against a parasitic infection. The shot has been in the works since 1987, at a cost of more than $750 million, mostly funded by the Bill and Melinda Gates Foundation and GlaxoSmithKline. Dubbed Mosquirix, it was recommended for approval by the World Health Organization in October, after a field trial involving 800,000 children in Ghana, Kenya and Malawi. The four-dose regimen was found to cut the risk of infection by 40% and the risk of severe infection by 30%. —Jeffrey Kluger
- Inside Mississippi's Last Abortion Clinic—and the Biggest Fight for Abortion Rights in a Generation
- Do Current COVID-19 Tests Still Detect Omicron?
- The First U.S. Offshore Wind Farm Could Be a Lifeline for Struggling New England Cities
- Welcome to TV's Era of Peak Redundancy
- The Key Role a Local Newspaper Played in the Trial Over Ahmaud Arbery's Murder
- TIME's Top 100 Photos of 2021
- 2021: The Year the Grift Kept Giving